Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Mirae Asset Global Investments

Investor type Investment Bank
Founders Hyeon-Joo Park


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 63
Average round size
The average size of a deal this fund participated in
Portfolio companies 52
Rounds per year 2.52
Lead investments 3
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 7
Key employees 14

Areas of investment

  • Biotechnology
  • Health Care
  • Software
  • Therapeutics
  • Food and Beverage

Mirae Asset Global Investments appeared to be the VC, which was created in 1997. The leading representative office of defined VC is situated in the Seoul. The venture was found in Asia in South Korea.

The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Mirae Asset Global Investments, startups are often financed by Eight Roads Ventures, Jungle Ventures, Venrock. The meaningful sponsors for the fund in investment in the same round are Mirae Asset Venture Investment, Eight Roads Ventures, ArrowMark Partners. In the next rounds fund is usually obtained by Troy Capital Partners, Toyota Motor Corporation, Tiller Partners.

The overall number of key employees were 14.

The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Among the most popular portfolio startups of the fund, we may highlight Vividion Therapeutics, BIOMx, Mesh Korea. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most successful fund investment fields, there are Medical, Android.

The fund is constantly included in 2-6 deals per year. The typical startup value when the investment from Mirae Asset Global Investments is more than 1 billion dollars. Comparing to the other companies, this Mirae Asset Global Investments performs on 10 percentage points less the average number of lead investments. The high activity for fund was in 2018. The real fund results show that this VC is 1 percentage points less often commits exit comparing to other companies. Deals in the range of 50 - 100 millions dollars are the general things for fund. The top amount of exits for fund were in 2019.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Mirae Asset Global Investments:
Typical Co-investors
Mirae Asset Global Investments is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Mirae Asset Global Investments:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
CFII Beijing, Beijing, China
China Internet Investment Fund Beijing, Beijing, China
Claridge Israel Herzliya, Israel, Tel Aviv
Danaher District of Columbia, United States, Washington
Dyrdek Machine Beverly Hills, California, United States
Financial Technology Partners California, San Francisco, United States
Hangzhou Joyni Capital Management China, Hangzhou, Zhejiang
Hillsven Capital California, San Francisco, United States
Jetta Company Limited Bonner Springs, Kansas, United States
Milestone Venture Capital Bayern, Germany, Hösbach
MK Energy and Infrastructure Connecticut, Stamford, United States
Olive Ventures Central, Central Region, Singapore
Pincus Capital Management -
Salkantay Ventures -
The Abell Venture Fund -
U.S. Cellular Chicago, Illinois, United States
Vintage Investment Partners Herzliya, Israel, Tel Aviv
Wipro Consumer Care and Lighting Bangalore, India, Karnataka
Yellowdog -
Yoshimasu Seisakusho Japan, Tokyo

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Casma Therapeutics

Health Care
$46M15 Nov 2022 Cambridge, Massachusetts, United States

Farizon Auto

Autonomous Vehicles
Clean Energy
Electric Vehicle
$300M26 Oct 2022 Hangzhou, Zhejiang, China


Food and Beverage
Food Delivery
$25M17 Oct 2022 South Korea, Gangwon-do, South Korea


Consumer Lending
Financial Services
$140M11 Oct 2022 Jakarta, Jakarta Raya, Indonesia

PI Industries Ltd.

$41M23 Sep 2022 Gurgaon, Haryana, India

Artificial Intelligence
Information Technology
Location Based Services
Machine Learning
Mapping Services
$3M19 Sep 2022 Singapore, Central, Singapore

Jai Kisan

Financial Services
$50M28 Jul 2022 Mumbai, Maharashtra, India


Health Care
$15M19 Jul 2022 Bangalore, Karnataka, India

Artificial Intelligence
Information Technology
Location Based Services
Machine Learning
Mapping Services
$21M23 May 2022 Singapore, Central, Singapore
Immunitas Therapeutics Closes $58M in Series B Financing

– Immunitas Therapeutics, a Waltham, MA-based single cell genomics-based therapeutics company, closed a $58m Series B financing.
– The round was led by Agent Capital with participation from Medical Excellence Capital (MEC), 120 Capital, Solasta Ventures, Mirae Asset, Ono Venture Investment, The Mark Foundation for Cancer Research, NS Investment, BrightEdge (American Cancer Society), and The Leukemia & Lymphoma Society . Existing investors Alexandria Venture Investments, Evotec, Leaps by Bayer, M Ventures, Novartis Venture Fund (NVF), and founding investor Longwood Fund also joined the round.
– The company intends to use the funds to advance its lead program, IMT-009, a CD161 inhibitor, into the clinic to treat both solid tumors and hematological malignancies.

FalconX Raises $210M Following 30x YoY Revenue Growth; Now Valued at $3.75 Billion

– FalconX announced a $210m Series C financing round, valuing the company at $3.75bn.
– The round was led by Altimeter Capital, Sapphire Ventures and existing investors B Capital Group and Tiger Global Management, with participation from Mirae Asset. Amex Ventures also increased its existing investment as part of this round.
– FalconX is a digital assets and cryptocurrency financial services company that provides institutions trading, credit, and clearing across major cryptocurrencies.
– FalconX will use the funding from the Series C round to expand its product lines, explore strategic acquisitions, and continue to hire great talent globally, including key executives with backgrounds at the convergence of traditional financial markets, digital assets and technology.
– FalconX was founded in 2016 by a team of ex-Goldman Sachs bankers and technologists.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Mirae Asset Global Investments?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: